Long‐Term Safety of Teriflunomide in Multiple Sclerosis Patients: Results of Prospective Comparative Studies in Three European Countries
Melinda Magyari(University of Copenhagen), Philippe Autier(International Prevention Research Institute), Antoine Duclos(Université Claude Bernard Lyon 1), Alice Koechlin(International Prevention Research Institute), El Maâti Allaoui(Intermutualist Agency), Stéphanie Polazzi(Université Claude Bernard Lyon 1), Pierrette Seeldrayers(European Platform of Women Scientists), Tine Iskov Kopp(Frederiksberg Hospital)
Cited by 3
Related Papers
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
|The Lancet|2001|1.1k
Worldwide Incidence and Prevalence of Neuromyelitis Optica
|Neurology|2020|303
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis
|JAMA Neurology|2021|237
Apparent changes in the epidemiology and severity of multiple sclerosis
|Nature Reviews Neurology|2021|209
Comorbidity in Multiple Sclerosis
|Frontiers in Neurology|2020|204